Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: ERN, ERP, DIV

Select Medical Holdings Corporation Announces Results For Its First Quarter Ended March 31, 2024 and Cash Dividend


MECHANICSBURG, Pa., May 2, 2024 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its first quarter ended March 31, 2024, and the declaration of a cash dividend.

For the first quarter ended March 31, 2024, revenue increased 7.4% to $1,788.8 million, compared to $1,665.0 million for the same quarter, prior year. Income from operations increased 28.1% to $194.0 million for the first quarter ended March 31, 2024, compared to $151.5 million for the same quarter, prior year. Net income increased 37.4% to $117.2 million for the first quarter ended March 31, 2024, compared to $85.3 million for the same quarter, prior year. Adjusted EBITDA increased 22.4% to $261.9 million for the first quarter ended March 31, 2024, compared to $214.1 million for the same quarter, prior year. Earnings per common share increased 33.9% to $0.75 for the first quarter ended March 31, 2024, compared to $0.56 for the same quarter, prior year. Adjusted earnings per common share increased 37.5% to $0.77 for the first quarter ended March 31, 2024, compared to $0.56 for the same quarter, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table VI of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table VII of this release.

Company Overview

Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on number of facilities.   Select Medical's reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As of March 31, 2024, Select Medical operated 107 critical illness recovery hospitals in 28 states, 33 rehabilitation hospitals in 13 states, 1,922 outpatient rehabilitation clinics in 39 states and the District of Columbia, and 547 occupational health centers in 41 states. At March 31, 2024, Select Medical had operations in 46 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.

Critical Illness Recovery Hospital Segment

For the first quarter ended March 31, 2024, revenue for the critical illness recovery hospital segment increased 10.4% to $655.9 million, compared to $593.9 million for the same quarter, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 51.0% to $115.9 million for the first quarter ended March 31, 2024, compared to $76.8 million for the same quarter, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 17.7% for the first quarter ended March 31, 2024, compared to 12.9% for the same quarter, prior year. Certain critical illness recovery hospital key statistics are presented in table V of this release for the first quarters ended March 31, 2024 and 2023.

Rehabilitation Hospital Segment

For the first quarter ended March 31, 2024, revenue for the rehabilitation hospital segment increased 14.8% to $265.7 million, compared to $231.5 million for the same quarter, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 30.0% to $61.4 million for the first quarter ended March 31, 2024, compared to $47.2 million for the same quarter, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 23.1% for the first quarter ended March 31, 2024, compared to 20.4% for the same quarter, prior year. Certain rehabilitation hospital key statistics are presented in table V of this release for the first quarters ended March 31, 2024 and 2023.

Outpatient Rehabilitation Segment

For the first quarter ended March 31, 2024, revenue for the outpatient rehabilitation segment increased 2.5% to $303.2 million, compared to $295.9 million for the same quarter, prior year. Adjusted EBITDA for the outpatient rehabilitation segment was $24.9 million for the first quarter ended March 31, 2024, compared to $30.2 million for the same quarter, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 8.2% for the first quarter ended March 31, 2024, compared to 10.2% for the same quarter, prior year. Certain outpatient rehabilitation key statistics are presented in table V of this release for the first quarters ended March 31, 2024 and 2023.

Concentra Segment

For the first quarter ended March 31, 2024, revenue for the Concentra segment increased 2.5% to $467.6 million, compared to $456.3 million for the same quarter, prior year. Adjusted EBITDA for the Concentra segment increased 2.6% to $96.1 million for the first quarter ended March 31, 2024, compared to $93.7 million for the same quarter, prior year. The Adjusted EBITDA margin for the Concentra segment was 20.6% for the first quarter ended March 31, 2024, compared to 20.5% for the same quarter, prior year. Certain Concentra key statistics are presented in table V of this release for the first quarters ended March 31, 2024 and 2023.

Dividend

On May 1, 2024, Select Medical's Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about May 30, 2024, to stockholders of record as of the close of business on May 16, 2024.

There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of Select Medical's Board of Directors after taking into account various factors, including, but not limited to, Select Medical's financial condition, operating results, available cash and current and anticipated cash needs, the terms of Select Medical's indebtedness, and other factors Select Medical's Board of Directors may deem to be relevant.

Stock Repurchase Program

The Board of Directors of Select Medical has authorized a common stock repurchase program to repurchase up to $1.0 billion worth of shares of its common stock. The common stock repurchase program will remain in effect until December 31, 2025, unless further extended or earlier terminated by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Select Medical deems appropriate. Select Medical funds this program with cash on hand and borrowings under its revolving credit facility.

Select Medical did not repurchase shares under its authorized stock repurchase program during the three months ended March 31, 2024. Since the inception of the common stock repurchase program through March 31, 2024, Select Medical has repurchased 48,234,823 shares at a cost of approximately $600.3 million, or $12.45 per share, which includes transaction costs.

Business Outlook

Select Medical is reaffirming its 2024 business outlook for revenue and adjusting its 2024 business outlook for Adjusted EBITDA and fully diluted earnings per share, which was provided most recently in its February 22, 2024, press release. Select Medical is also issuing its business outlook for adjusted earnings per share. Select Medical expects revenue to be in the range of $6.9 billion to $7.1 billion, Adjusted EBITDA to be in the range of $845 million to $885 million, fully diluted earnings per share to be in the range of $1.95 to $2.19 and adjusted earnings per share to be in the range of $1.96 to $2.20. Reconciliations of full year 2024 Adjusted EBITDA expectations to net income and adjusted earnings per share to fully diluted earnings per share are presented in table VIII of this release.

Conference Call

Select Medical will host a conference call regarding its first quarter results and its business outlook on Friday, May 3, 2024, at 9:00am ET. The conference call will be a live webcast and can be accessed at Select Medical Holdings Corporation's website at www.selectmedicalholdings.com. A replay of the webcast will be available shortly after the call through the same link.

For listeners wishing to dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Select Medical Earnings Call Registration to obtain your dial-in number and unique passcode.

Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Select Medical's 2024 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investor inquiries:
Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
[email protected]

 

I.  Condensed Consolidated Statements of Operations

For the Three Months Ended March 31, 2023 and 2024

(In thousands, except per share amounts, unaudited)




2023


2024


% Change

Revenue


$             1,664,980


$             1,788,809


7.4 %

Costs and expenses:







Cost of services, exclusive of depreciation and amortization


1,418,819


1,494,610


5.3

General and administrative


42,279


48,447


14.6

Depreciation and amortization


52,425


54,069


3.1

Total costs and expenses


1,513,523


1,597,126


5.5

Other operating income


?


2,284


N/M

Income from operations


151,457


193,967


28.1

Other income and expense:







Equity in earnings of unconsolidated subsidiaries


8,556


10,421


21.8

Interest expense


(48,571)


(50,763)


4.5

Income before income taxes


111,442


153,625


37.9

Income tax expense


26,185


36,458


39.2

Net income


85,257


117,167


37.4

Less: Net income attributable to non-controlling interests


14,452


20,270


40.3

Net income attributable to Select Medical


$                  70,805


$                  96,897


36.9 %

Basic and diluted earnings per common share:(1)


$                       0.56


$                       0.75









(1)

Refer to table II for calculation of earnings per common share.

N/M

Not meaningful

 

II.  Earnings per Share

For the Three Months Ended March 31, 2023 and 2024
(In thousands, except per share amounts, unaudited)

Select Medical's capital structure includes common stock and unvested restricted stock awards. To compute earnings per share ("EPS"), Select Medical applies the two-class method because its unvested restricted stock awards are participating securities which are entitled to participate equally with its common stock in undistributed earnings.

The following table sets forth the net income attributable to Select Medical, its common shares outstanding, and its participating securities outstanding for the three months ended March 31, 2023 and 2024:


Basic and Diluted EPS


Three Months Ended

March 31,


2023


2024

Net income

$                           85,257


$                         117,167

Less: net income attributable to non-controlling interests

14,452


20,270

Net income attributable to Select Medical

70,805


96,897

Less: net income attributable to participating securities

2,573


3,398

Net income attributable to common shares

$                           68,232


$                           93,499

The following tables set forth the computation of EPS under the two-class method for the three months ended March 31, 2023 and 2024:



Three Months Ended March 31,



2023



2024



Net Income
Allocation


Shares(1)


Basic and
Diluted EPS



Net Income
Allocation


Shares(1)


Basic and
Diluted EPS



(in thousands, except for per share amounts)

Common shares


$         68,232


122,553


$              0.56



$            93,499


123,859


$              0.75

Participating securities


2,573


4,622


$              0.56



3,398


4,501


$              0.75

Total


$         70,805







$            96,897







(1)

Represents the weighted average share count outstanding during the period.

 

III.  Condensed Consolidated Balance Sheets

(In thousands, unaudited)




December 31, 2023


March 31, 2024

Assets





Current Assets:





Cash and cash equivalents


$                       84,006


$                       92,620

Accounts receivable


940,335


1,134,788

Other current assets


233,305


212,932

Total Current Assets


1,257,646


1,440,340

Operating lease right-of-use assets


1,188,616


1,176,713

Property and equipment, net


1,023,561


1,024,626

Goodwill


3,513,170


3,517,071

Identifiable intangible assets, net


329,916


324,125

Other assets


376,722


375,388

Total Assets


$                 7,689,631


$                 7,858,263

Liabilities and Equity





Current Liabilities:





Payables and accruals


$                     932,736


$                     878,576

Current operating lease liabilities


245,400


245,617

Current portion of long-term debt and notes payable


70,329


60,184

Total Current Liabilities


1,248,465


1,184,377

Non-current operating lease liabilities


1,025,867


1,015,160

Long-term debt, net of current portion


3,587,675


3,758,631

Non-current deferred tax liability


143,306


133,987

Other non-current liabilities


110,303


100,175

Total Liabilities


6,115,616


6,192,330

Redeemable non-controlling interests


26,297


28,290

Total equity


1,547,718


1,637,643

Total Liabilities and Equity


$                 7,689,631


$                 7,858,263

 

IV.  Condensed Consolidated Statements of Cash Flows

For the Three Months Ended March 31, 2023 and 2024

(In thousands, unaudited)




2023


2024

Operating activities





Net income


$                       85,257


$                     117,167

Adjustments to reconcile net income to net cash provided by (used in) operating activities:





Distributions from unconsolidated subsidiaries


2,566


12,374

Depreciation and amortization


52,425


54,069

Provision for expected credit losses


429


854

Equity in earnings of unconsolidated subsidiaries


(8,556)


(10,421)

(Gain) loss on sale or disposal of assets


(7)


44

Stock compensation expense


10,181


11,610

Amortization of debt discount, premium, and issuance costs


565


750

Deferred income taxes


(2,601)


(6,891)

Changes in operating assets and liabilities, net of effects of business combinations:





Accounts receivable


(55,397)


(195,308)

Other current assets


(11,742)


(9,611)

Other assets


3,659


2,363

Accounts payable and accrued expenses


(25,339)


(43,689)

Net cash provided by (used in) operating activities


51,440


(66,689)

Investing activities





Business combinations, net of cash acquired


(397)


(5,405)

Purchases of property, equipment, and other assets


(58,885)


(52,517)

Investment in businesses


(9,800)


?

Proceeds from sale of assets and businesses


20


265

Net cash used in investing activities


(69,062)


(57,657)

Financing activities





Borrowings on revolving facilities


225,000


495,000

Payments on revolving facilities


(210,000)


(265,000)

Payments on term loans


?


(79,085)

Borrowings of other debt


21,448


17,728

Principal payments on other debt


(11,170)


(9,061)

Dividends paid to common stockholders


(15,897)


(16,045)

Decrease in overdrafts


(724)


(1,740)

Proceeds from issuance of non-controlling interests


2,731


4,002

Distributions to and purchases of non-controlling interests


(7,969)


(12,839)

Net cash provided by financing activities


3,419


132,960

Net increase (decrease) in cash and cash equivalents


(14,203)


8,614

Cash and cash equivalents at beginning of period


97,906


84,006

Cash and cash equivalents at end of period


$                       83,703


$                       92,620

Supplemental information





Cash paid for interest, excluding amounts received of $17,828 and $22,515 under the interest rate cap contract


$                       84,531


$                       88,834

Cash paid for taxes


336


604

 

V.  Key Statistics

For the Three Months Ended March 31, 2023, and 2024

(unaudited)




2023


2024


% Change

Critical Illness Recovery Hospital







Number of hospitals operated ? end of period(a)


105


107



Revenue (,000)


$        593,926


$        655,880


10.4 %

Number of patient days(b)(c)


286,746


294,622


2.7 %

Number of admissions(b)(d)


9,438


9,529


1.0 %

Revenue per patient day(b)(e)


$            2,058


$            2,219


7.8 %

Occupancy rate(b)(f)


72 %


71 %


(1.4) %

Adjusted EBITDA (,000)


$          76,773


$        115,940


51.0 %

Adjusted EBITDA margin


12.9 %


17.7 %



Rehabilitation Hospital







Number of hospitals operated ? end of period(a)


32


33



Revenue (,000)


$        231,462


$        265,700


14.8 %

Number of patient days(b)(c)


107,910


116,844


8.3 %

Number of admissions(b)(d)


7,620


8,275


8.6 %

Revenue per patient day(b)(e)


$            1,969


$            2,096


6.4 %

Occupancy rate(b)(f)


86 %


87 %


1.2 %

Adjusted EBITDA (,000)


$          47,216


$          61,400


30.0 %

Adjusted EBITDA margin


20.4 %


23.1 %



Outpatient Rehabilitation







Number of clinics operated ? end of period(a)


1,936


1,922



Working days(g)


64


64



Revenue (,000)


$        295,903


$        303,158


2.5 %

Number of visits(b)(h)


2,636,770


2,735,126


3.7 %

Revenue per visit(b)(i)


$               101


$                  99


(2.0) %

Adjusted EBITDA (,000)


$          30,199


$          24,928


(17.5) %

Adjusted EBITDA margin


10.2 %


8.2 %



Concentra







Number of centers operated ? end of period(b)


539


547



Working days(g)


64


64



Revenue (,000)


$        456,298


$        467,598


2.5 %

Number of visits(b)(h)


3,217,945


3,155,655


(1.9) %

Revenue per visit(b)(i)


$               133


$               139


4.5 %

Adjusted EBITDA (,000)


$          93,748


$          96,142


2.6 %

Adjusted EBITDA margin


20.5 %


20.6 %













(a)

Includes managed locations.

(b)

Excludes managed locations. For purposes of the Concentra segment, onsite clinics are excluded.

(c)

Each patient day represents one patient occupying one bed for one day during the periods presented.

(d)

Represents the number of patients admitted to Select Medical's hospitals during the periods presented.

(e)

Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at Select Medical's hospitals, by the total number of patient days.

(f)

Represents the portion of our hospitals being utilized for patient care during the periods presented. Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented.

(g)

Represents the number of days in which normal business operations were conducted during the periods presented.

(h)

Represents the number of visits in which patients were treated at Select Medical's outpatient rehabilitation clinics and Concentra centers during the periods presented.

(i)

Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes of this computation for the Concentra segment, patient service revenue does not include onsite clinics.

 

VI. Net Income to Adjusted EBITDA Reconciliation

For the Three Months Ended March 31, 2023 and 2024
(In thousands, unaudited) 

The presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of Select Medical's segments. Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States of America ("GAAP"). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

The following table reconciles net income to Adjusted EBITDA for Select Medical. Adjusted EBITDA is used by Select Medical to report its segment performance. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, transaction costs associated with the Concentra separation, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.


Three Months Ended

March 31,



2023


2024

Net income


$                      85,257


$                    117,167

Income tax expense


26,185


36,458

Interest expense


48,571


50,763

Equity in earnings of unconsolidated subsidiaries


(8,556)


(10,421)

Income from operations


151,457


193,967

Stock compensation expense:





Included in general and administrative


8,405


9,682

Included in cost of services


1,776


1,928

Depreciation and amortization


52,425


54,069

Concentra separation transaction costs(b)


?


2,271

Adjusted EBITDA


$                    214,063


$                    261,917






Critical illness recovery hospital


$                      76,773


$                    115,940

Rehabilitation hospital


47,216


61,400

Outpatient rehabilitation


30,199


24,928

Concentra


93,748


96,142

Other(a)


(33,873)


(36,493)

Adjusted EBITDA


$                    214,063


$                    261,917











(a)

Other primarily includes general and administrative costs.

(b)

Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company's planned separation of the Concentra segment into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations.

 

VII. Reconciliation of Earnings per Common Share to Adjusted Earnings per Common Share

For the Three Months Ended March 31, 2023 and 2024
(In thousands, except per share amounts, unaudited) 

Adjusted net income attributable to common shares and adjusted earnings per common share are not measures of financial performance under GAAP. Items excluded from adjusted net income attributable to common shares and adjusted earnings per common share are significant components in understanding and assessing financial performance. Select Medical believes that the presentation of adjusted net income attributable to common shares and adjusted earnings per common share are important to investors because they are reflective of the financial performance of Select Medical's ongoing operations and provide better comparability of its results of operations between periods. Adjusted net income attributable to common shares and adjusted earnings per common share should not be considered in isolation or as alternatives to, or substitutes for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because adjusted net income attributable to common shares and adjusted earnings per common share are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, adjusted net income attributable to common shares and adjusted earnings per common share as presented may not be comparable to other similarly titled measures of other companies.

The following tables reconcile net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted earnings per common share on a fully diluted basis.


Three Months Ended March 31,



2023


Per Share(a)


2024


Per Share(a)


Net income attributable to common shares(a)

$           68,232


$               0.56


$           93,499


$               0.75


Adjustments:(b)









Concentra separation transaction costs, net of tax

?


?


1,619


0.01


Adjusted net income attributable to common shares

$           68,232


$               0.56


$           95,118


$               0.77

(c)











(a)

Net income attributable to common shares and earnings per common share are calculated based on the weighted average common shares outstanding, as presented in table II.

(b)

Adjustments to net income attributable to common shares include estimated income tax and non-controlling interest impacts and are calculated based on the diluted weighted average common shares outstanding. The estimated income tax impact, which is determined using tax rates based on the nature of the adjustment and the jurisdiction in which the adjustment occurred, includes both current and deferred income tax expense or benefit.

(c)

Does not total due to rounding.

 

VIII. Net Income to Adjusted EBITDA and Earnings per Common Share to Adjusted Earnings per Common Share
Reconciliations

Business Outlook for the Year Ending December 31, 2024
(In millions, unaudited)

The following are reconciliations of full year 2024 Adjusted EBITDA and adjusted earnings per common share expectations as computed at the low and high points of the range to the closest comparable GAAP financial measure. Refer to table VI and VII for discussion of Select Medical's use of Adjusted EBITDA and adjusted earnings per common share in evaluating financial performance. Refer to table VI for the definition of Adjusted EBITDA. Each item presented in the below table is an estimation of full year 2024 expectations. 


Range

Non-GAAP Measure Reconciliation

Low


High

Net income attributable to Select Medical

$                            252


$                            284

Net income attributable to non-controlling interests

68


69

Net income

320


353

Income tax expense

96


105

Interest expense

218


218

Equity in earnings of unconsolidated subsidiaries

(43)


(45)

Income from operations

591


631

Stock compensation expense

48


48

Depreciation and amortization

204


204

Concentra separation transaction costs(a)

2


2

Adjusted EBITDA

$                            845


$                            885



Range

Non-GAAP Measure Reconciliation

Low


High

Basic and diluted earnings per common share

$                           1.95


$                           2.19

Adjustments:




Concentra separation transaction costs, net of tax (a)

0.01


0.01

Adjusted earnings per common share

$                           1.96


$                           2.20











(a)

Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company's planned separation of the Concentra Segment into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations. The transaction costs reflect the costs incurred by the Company during the three months ended March 24, 2024, and they do not include an estimate of costs to be incurred during the remainder of 2024.

 

SOURCE - Select Medical Holdings Corporation


These press releases may also interest you

at 00:01
Graduates who went to medical school for three years performed equally well on tests of skill and knowledge as their peers who followed a four-year program, a new study shows....

14 oct 2024
Aidoc, a global pioneer in clinical AI solutions, today announced the expansion of its partnership with Integral Diagnostics (IDX), the leading provider of AI-driven medical imaging services, across Australia and New Zealand. This enhanced...

14 oct 2024
PharmAbcine, Inc. (KOSDAQ: 208340), a clinical-stage public company developing next-generation therapeutics to address unmet medical needs, today...

14 oct 2024
At the World Health Summit in Berlin today (15 October), the Pasteur Network (PN) announced the launch of a pioneering project to empower local researchers, governments and communities in low- and middle-income countries to tackle the health impacts...

14 oct 2024
Report with the AI impact on market trends- The global industrial enzymes market  size is estimated to grow by USD 2.25 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 6.1%  during the forecast...

14 oct 2024
Inland Empire Health Plan (IEHP) team members, family and friends hit the streets of Murrieta in support of breast cancer awareness at the annual Susan G. Komen MORE THAN PINK Walk on Oct. 13....



News published on and distributed by: